KRAS and colorectal carcinoma: Furthermore, recent studies have shown that KRAS-mutant CRC have significantly reduced infiltration of naïve B cells, macrophage M1, activated CD4 T cells, cytotoxic cells and neutrophils, and obviously increased regulatory T cells compared to patients with KRAS wild-type CRC [128, 129].